AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal ("GI") diseases, announced today the release of a Company overview as presented by AzurRx's President & CEO, Thijs Spoor.
Mr. Spoor began the communication by stating, "This Company overview serves to provide shareholders with a perspective on AzurRx, its evolution and future potential. Let me begin with the fundamentals. We have a clear, focused plan for value creation, building our pipeline assets with a short-term, lower-risk development pathway, an experienced management team and first-class advisors.
We believe that our focus on non-systemic therapies represents a new frontier for developing therapies. Our pipeline, led by MS1819 and followed by AZX1101, is moving ahead and we have further strengthened and we continue to expand our global patent portfolio. Non-absorbable drugs are a unique subset of orally administered agents that exert their therapeutic effects locally in the GI tract. In contrast to traditional drugs, which are designed to be rapidly absorbed, achieve therapeutic plasma levels, and then be eliminated by multiple pathways, non-absorbable drugs are designed to only act locally in the gut. It is our belief that if drugs are not absorbed into the bloodstream, then it is very difficult for them to reach the liver, heart, brain or other organs, and thus we believe that the chance of having serious side effects is decreased. Read this full Press Release and more about the MS1819 & AZX1101 developments and advancements at: http://marketnewsupdates.com/news/azrx.html
In other Biotech and Big Pharma positive performers of note this week:
Pfizer Inc. (NYSE: PFE) yesterday announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin. The trial demonstrated equivalence in the primary endpoint of objective response rate (ORR) of PF-05280014 versus Herceptin, taken in combination with paclitaxel, in first line patients with HER2-positive metastatic breast cancer. ORR is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum period of time.
Novo Nordisk's (NYSE: NVO) long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday. Type 2 diabetics who need insulin to control their blood sugar risk having too low levels of glucose in their blood, which can cause tiredness, confusion and in some cases unconsciousness. The so-called DEVOTE study, involving more than 7,500 patients, demonstrated Tresiba's non-inferiority of major adverse cardiovascular events to rival Sanofi's long-acting insulin Lantus (insulin glargine), Novo said.
Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, this week announced its financial results for the second quarter ended October 31, 2016. Joel Ackerman, CEO of Champions, commented, "This was truly a milestone quarter for Champions. We have been focused over the last 2 years on achieving profitability while continuing to invest in expanding our technology and products. We reached this important step in the Company's evolution by growing our customer base, delivering high quality studies and managing our costs. With 50% revenue growth and a lower cost base than last year, we have delivered on this ambitious objective ahead of schedule. Looking forward, we remain confident we will achieve our projected revenue of $16 - 18 million for our fiscal year ending April 2017.
Genetic Technologies Limited (NASDAQ: GENE), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, this week announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated one thousand seven hundred dollars for news coverage of the current press release issued by AzurRx BioPharma, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact email: firstname.lastname@example.org - +1(561)325-8757